Zhongnan Medical Journal Press

Home Results

A total of 7 result was found. Results that relate to Bevacizumab

A case report of anaphylactic shock induced by bevacizumab

Published on Chinese Journal of Pharmacoepidemiology 2023,32(1):103-106.
7711 times 3611 times

Jing-Jing LIU Yan-Sheng KANG Xiao-Qin WANG Wei ZHANG He-Feng ZHANG Tong WANG

Bevacizumab Anaphylactic shock Adverse drug reactions Case report
Details
Case analysis of abnormal increase in blood glucose after targeted combination chemotherapy in a patient with colon cancer

Published on Chinese Journal of Pharmacoepidemiology 2024,33(2):230-235.
7649 times 2349 times

WU Yan WANG Xin

Diabetic ketoacidosis High blood sugar Fluorouracil Bevacizumab
Details
Efficacy and safety of bevacizumab biosimilars versus original drugs for patients with metastatic colorectal cancer: a Meta-analysis

Published on Chinese Journal of Pharmacoepidemiology 2023,32(12):1401-1407.
7631 times 1531 times

En-Hui WEN Ying LI Zhi-Ying WANG Li-Hui LONG

Bevacizumab Biosimilar Metastatic colorectal cancer Meta-analysis Randomized controlled trial
Details
Evaluation of efficacy and safety of Sintilimab+Bevacizumab combined with PP regime in patients with advanced non-squamous non-small cell lung cancer

Published on Frontiers in Pharmaceutical Sciences 2024,27(1):93-99.
4648 times 1204 times

SHEN Junjie JIN Jianwei RUAN Zekun ZHANG Weiping

Advanced non-squamous non-small lung cell cancer Sintilimab Bevacizumab Efficay Safety
Details
Real-world study of sintilimab combined with bevacizumab in patients with advanced hepatocellular carcinoma

Published on Frontiers in Pharmaceutical Sciences 2024,27(3):485-490.
7902 times 1715 times

SU Zhan CHE Jinhui PEI Ruifeng

Advanced hepatocellular carcinoma Sintilimab Bevacizumab Clinical efficacy Safety Overall survival Progression-free survival
Details
Comparative study of two antiangiogenic agents combined with pemetrexed and carboplatin in patients with EGFR-TKI-acquired resistant advanced lung adenocarcinoma

Published on Frontiers in Pharmaceutical Sciences 2024,27(7):1162-1169.
8175 times 1514 times

XIONG Jufang GUO Xingyu ZHOU Meiying

Anrotinib Bevacizumab EGFR-TKI resistance Advanced lung adenocarcinoma Acquired drug-resistance
Details
Pharmaceutical practice of bevacizumab-induced refractory hypertension and proteinuria in a patient with advanced lung adenocarcinoma

Published on Chinese Journal of Pharmacoepidemiology 2025,34(11):1335-1339.
557 times 104 times

YAN Jiaju YUAN Yongyong LIU Meng

Bevacizumab Lung adenocarcinoma Resistant hypertension Proteinuria Phamaceutical care
Details